NASDAQ:IFRX - Inflarx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inflarx NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.27 +0.11 (+3.48 %) (As of 12/9/2019 04:00 PM ET) Add Compare Today's Range$3.17Now: $3.27▼$3.3550-Day Range$2.20MA: $2.71▼$3.4752-Week Range$2.17Now: $3.27▼$53.10Volume6,820 shsAverage Volume979,295 shsMarket Capitalization$84.89 millionP/E RatioN/ADividend YieldN/ABeta-1.27 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IFRX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.inflarx.de/ Phone49-36-4150-8180Debt Debt-to-Equity RatioN/A Current Ratio7.81 Quick Ratio7.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.64 per share Price / Book0.43Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-35,210,000.00 Net MarginsN/A Return on Equity-35.75% Return on Assets-32.84%Miscellaneous Employees36 Outstanding Shares25,960,000Market Cap$84.89 million Next Earnings Date3/26/2020 (Estimated) OptionableNot Optionable Receive IFRX News and Ratings via Email Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IFRX Rates by TradingView Inflarx (NASDAQ:IFRX) Frequently Asked Questions What is Inflarx's stock symbol? Inflarx trades on the NASDAQ under the ticker symbol "IFRX." How were Inflarx's earnings last quarter? Inflarx NV (NASDAQ:IFRX) released its quarterly earnings data on Thursday, August, 9th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.24. View Inflarx's Earnings History. When is Inflarx's next earnings date? Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Inflarx. What price target have analysts set for IFRX? 9 brokerages have issued 12-month price objectives for Inflarx's stock. Their forecasts range from $5.00 to $47.00. On average, they anticipate Inflarx's share price to reach $17.43 in the next year. This suggests a possible upside of 433.0% from the stock's current price. View Analyst Price Targets for Inflarx. What is the consensus analysts' recommendation for Inflarx? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 2 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inflarx. Has Inflarx been receiving favorable news coverage? News articles about IFRX stock have been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inflarx earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Inflarx. Are investors shorting Inflarx? Inflarx saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,320,000 shares, a decline of 7.0% from the October 31st total of 1,420,000 shares. Based on an average daily trading volume, of 500,500 shares, the days-to-cover ratio is currently 2.6 days. Currently, 7.5% of the company's shares are sold short. View Inflarx's Current Options Chain. Who are some of Inflarx's key competitors? Some companies that are related to Inflarx include Avid Bioservices (CDMO), Evofem Biosciences (EVFM), Geron (GERN), Puma Biotechnology (PBYI), Kindred Biosciences (KIN), Kamada (KMDA), CytomX Therapeutics (CTMX), Mallinckrodt (MNK), Fulcrum Therapeutics (FULC), Neptune Wellness Solutions (NEPT), Cue Biopharma (CUE), Albireo Pharma (ALBO), Galera Therapeutics (GRTX), GlycoMimetics (GLYC) and Seres Therapeutics (MCRB). What other stocks do shareholders of Inflarx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inflarx investors own include Global Blood Therapeutics (GBT), The Medicines (MDCO), Alibaba Group (BABA), Visa (V), AcelRx Pharmaceuticals (ACRX), Amarin (AMRN), Arrowhead Pharmaceuticals (ARWR), Bellicum Pharmaceuticals (BLCM), Exelixis (EXEL) and Amicus Therapeutics (FOLD). Who are Inflarx's key executives? Inflarx's management team includes the folowing people: Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)Mr. Arnd Christ, Chief Financial Officer (Age 53)Mr. Jason M. Marks J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 43)Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy When did Inflarx IPO? (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Inflarx's major shareholders? Inflarx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (1.93%), Millennium Management LLC (0.62%) and Barclays PLC (0.19%). Which institutional investors are selling Inflarx stock? IFRX stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Which institutional investors are buying Inflarx stock? IFRX stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and Millennium Management LLC. How do I buy shares of Inflarx? Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Inflarx's stock price today? One share of IFRX stock can currently be purchased for approximately $3.27. How big of a company is Inflarx? Inflarx has a market capitalization of $84.89 million. The company earns $-35,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Inflarx employs 36 workers across the globe.View Additional Information About Inflarx. What is Inflarx's official website? The official website for Inflarx is http://www.inflarx.de/. How can I contact Inflarx? Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180. MarketBeat Community Rating for Inflarx (NASDAQ IFRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 165 (Vote Outperform)Underperform Votes: 195 (Vote Underperform)Total Votes: 360MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/9/2019 by MarketBeat.com StaffFeatured Article: What is a stock split?
